# Coagulation Emergencies in Small Animals: Diagnosis and Management ## Key Takeaways - Rapid stabilization of perfusion and oxygenation is paramount in any bleeding patient before initiating diagnostic sampling. Point-of-care tests like buccal mucosal bleeding time, activated clotting time, and platelet estimates are crucial for immediate assessment. - Disseminated Intravascular Coagulation (DIC) is a complex acquired syndrome requiring both clinical context and laboratory evidence of consumption coagulopathy; no single test confirms its diagnosis. Treatment targets the underlying trigger and provides hemostatic support, often with fresh frozen plasma. - Anticoagulant rodenticide toxicity inhibits vitamin K epoxide reductase, leading to delayed bleeding; diagnosis is strongly suggested by a prolonged PT with a normal platelet count and buccal mucosal bleeding time. Vitamin K1 therapy is monitored by serial PT measurements. - Inherited coagulopathies, such as hemophilia A and B, typically present with a prolonged activated partial thromboplastin time (aPTT) and normal prothrombin time (PT), guiding suspicion towards intrinsic pathway factor deficiencies. - Fresh frozen plasma (FFP) is the primary hemostatic support for DIC and anticoagulant rodenticide toxicity, while cryoprecipitate is preferred for hemophilia A due to its concentrated factor VIII and fibrinogen content. - Transfusion monitoring in bleeding patients necessitates serial packed cell volume, total protein, coagulation times, and platelet counts at defined intervals to assess efficacy and detect complications like transfusion-associated circulatory overload. --- This article provides a decision-oriented framework for the emergency diagnosis and management of bleeding disorders in dogs and cats. It is written for the practicing veterinarian who must rapidly distinguish surgical bleeding from medical coagulopathy, initiate hemostatic support before laboratory confirmation, and anticipate the complications of transfusion therapy. The clinical questions addressed are those that arise at the point of care: which patient needs plasma, which needs a procoagulant drug, which needs surgery, and when should resuscitation stop. The scope covers the three dominant emergency presentations: disseminated intravascular coagulation (DIC), anticoagulant rodenticide toxicity, and inherited coagulopathies such as hemophilia and von Willebrand disease. Emphasis is placed on transfusion support, particularly fresh frozen plasma, and on the monitoring parameters that guide ongoing therapy. Routine coagulation testing in stable patients and chronic management of bleeding disorders are excluded. Where the evidence base is contested or extrapolated from human medicine, this is stated explicitly. ## At a Glance | Parameter | Key Decision or Fact | |---|---| | First action in any bleeding patient | Stabilize perfusion and oxygenation before diagnostic sampling | | Point-of-care tests | Buccal mucosal bleeding time, activated clotting time, platelet estimate, viscoelastic testing if available | | DIC diagnosis | Requires both clinical context and laboratory evidence of consumption coagulopathy, no single test confirms it | | Anticoagulant rodenticide | Vitamin K1 epoxide cycle inhibition, response to therapy is monitored by PT, not clinical appearance | | Inherited coagulopathy | Breed history and single-factor deficiency pattern guide suspicion, specific factor assays confirm | | Fresh frozen plasma | Contains labile factors V and VIII, appropriate for DIC and rodenticide toxicity | | Cryoprecipitate | Factor VIII and fibrinogen concentrate, preferred for hemophilia A when available | | Transfusion monitoring | Serial PCV, total protein, coagulation times, and platelet count at defined intervals | ## Hemostatic Physiology Relevant to Emergency Presentation The hemostatic system balances procoagulant and anticoagulant forces across three overlapping phases: primary hemostasis (platelet plug formation), secondary hemostasis (fibrin clot generation), and fibrinolysis. Emergency presentations arise when this balance shifts toward bleeding or thrombosis, often both simultaneously as in DIC. Primary hemostasis depends on platelet adhesion to exposed subendothelial collagen via von Willebrand factor, followed by platelet activation and aggregation. Defects in this phase produce mucosal bleeding, petechiae, and prolonged bleeding from small wounds. Secondary hemostasis involves the coagulation cascade, culminating in thrombin generation and fibrin polymerisation. Defects here produce deep tissue hematomas, joint bleeding, and body cavity hemorrhage. The distinction is clinically useful because it directs the initial differential diagnosis and the choice of transfusion product. The liver synthesises most coagulation factors, including the vitamin K dependent factors II, VII, IX, and X, plus proteins C and S. Factor VII has the shortest half-life, which explains why prothrombin time (PT) prolongs earliest in vitamin K antagonism. Factor VIII is produced by endothelium and megakaryocytes, so hepatic failure does not reduce it. This physiological separation matters when interpreting coagulation panels in bleeding patients. ## Disseminated Intravascular Coagulation ### Pathophysiology and Clinical Context DIC is an acquired syndrome of systemic intravascular coagulation activation, not a single disease. It consumes platelets and coagulation factors while simultaneously driving microvascular thrombosis and secondary fibrinolysis. The result is a patient who may bleed and thrombose at the same time. Common triggers in small animals include sepsis, pancreatitis, heatstroke, neoplasia, and massive tissue trauma. The clinical presentation is variable. Some patients show overt bleeding from venipuncture sites, mucosal surfaces, or surgical incisions. Others present with thrombotic complications such as acral necrosis or acute kidney injury. The diagnosis rests on a compatible underlying disease plus laboratory evidence of consumption: thrombocytopenia, prolonged PT and activated partial thromboplastin time (aPTT), low fibrinogen, and elevated fibrin degradation products or D-dimers. No single test confirms DIC, and the pattern must be interpreted in the context of the inciting cause. ### Emergency Diagnostic Approach In the emergency setting, a platelet estimate from a blood smear and an activated clotting time (ACT) can be performed within minutes. A low platelet count with prolonged ACT in a patient with a known DIC trigger supports the diagnosis. Viscoelastic testing, where available, may reveal a hypercoagulable or hypocoagulable profile and can guide product selection, but its availability in general practice remains limited. Treatment targets the underlying trigger and provides hemostatic support. Fresh frozen plasma supplies depleted factors and natural anticoagulants, though its benefit in DIC is debated because it may fuel ongoing coagulation. Platelet-rich plasma or platelet transfusion is indicated when thrombocytopenia is severe and bleeding is active. The evidence base for specific transfusion thresholds in veterinary DIC is thin, and decisions must be individualised. ## Anticoagulant Rodenticide Toxicity ### Mechanism and Clinical Progression Anticoagulant rodenticides inhibit vitamin K epoxide reductase, blocking the recycling of vitamin K and preventing the gamma-carboxylation of factors II, VII, IX, and X. The onset of bleeding is delayed by 24 to 72 hours after ingestion because circulating factors must be depleted first. Factor VII depletion occurs earliest, prolonging PT before aPTT becomes abnormal. Clinical signs reflect the site of hemorrhage: dyspnoea from pulmonary or pleural bleeding, lethargy from retroperitoneal or mediastinal hemorrhage, lameness from muscle hematomas, or collapse from pericardial or abdominal bleeding. A history of possible exposure is helpful, but its absence does not exclude the diagnosis. ### Diagnostic and Therapeutic Decisions A prolonged PT with a normal platelet count and normal buccal mucosal bleeding time strongly suggests vitamin K antagonism. The response to vitamin K1 therapy is monitored by repeat PT measurement at 48 to 72 hours. Patients with severe bleeding require fresh frozen plasma to provide active factors immediately, since vitamin K1 takes hours to restore hepatic synthesis. The duration of vitamin K1 therapy depends on the rodenticide type. First-generation compounds require shorter treatment than second-generation compounds with long half-lives. Current formulary and label references must be consulted for dosing and duration, and the specific product should be identified whenever possible. ## Inherited and Acquired Coagulation Factor Deficiencies ### Clinical Presentation and Triage Priorities Inherited coagulopathies in dogs and cats present with a characteriztic pattern of bleeding that distinguishes them from acquired disorders. Animals with factor VIII or factor IX deficiency typically show spontaneous haemarthrosis, muscle hematomas, and prolonged bleeding after minor trauma or surgery. Mucosal bleeding, epistaxis, and hematuria occur with variable frequency. The breed distribution provides the first diagnostic clue. Factor VIII deficiency (hemophilia A) is recognized in many breeds including German Shepherd Dogs, Golden Retrievers, and mixed-breed dogs, while factor IX deficiency (hemophilia B) is less common but well documented in British Shorthair cats and several canine breeds. Both are X-linked traits, so clinical disease appears almost exclusively in males, with females serving as carriers. The emergency presentation of an inherited coagulopathy is often a young male animal with acute lameness, a rapidly expanding soft tissue swelling, or bleeding that does not stop after venepuncture or a routine procedure. A littermate history of bleeding problems strengthens the suspicion. The physical examination should include a careful search for subcutaneous hematomas, joint effusion, and evidence of bleeding into body cavities. Thoracic auscultation and abdominal palpation may reveal effusion, and any animal with suspected retroperitoneal or mediastinal bleeding requires immediate assessment for hypovolemic shock. The critical triage decision is whether the patient needs immediate transfusion support before diagnostic confirmation. Any bleeding animal with tachycardia, pale mucous membranes, weak pulses, or a declining packed cell volume requires resuscitation in parallel with diagnostic testing. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on recognizing and staging hemorrhagic shock. A single normal coagulation profile does not exclude a mild factor deficiency, and repeat testing is warranted if clinical suspicion remains high. ### Diagnostic Confirmation and Factor-Specific Testing The initial coagulation profile in an inherited coagulopathy typically shows a prolonged activated partial thromboplastin time (aPTT) with a normal prothrombin time (PT) and normal platelet count. This pattern reflects the intrinsic pathway involvement of factors VIII and IX. A prolonged PT with normal aPTT suggests factor VII deficiency, which is rare but reported in Beagles and other breeds. Combined prolongation of PT and aPTT occurs with factor X, factor V, or factor II deficiency, and also with vitamin K-dependent factor depletion from rodenticide toxicity. One-stage factor assays provide definitive diagnosis but are not available in most emergency settings. Samples should be collected before transfusion whenever possible, since transfused plasma will transiently correct the measured factor activity and obscure the diagnosis. Citrated plasma should be separated promptly, frozen, and submitted to a reference laboratory. The clinician should record the timing of any prior transfusion on the submission form. Buccal mucosa bleeding time is normal in factor deficiencies because primary hemostasis is intact, and this test helps distinguish coagulopathies from thrombopathia or von Willebrand disease. ### Transfusion Strategy for Inherited Coagulopathies Fresh frozen plasma (FFP) is the mainstay of emergency treatment for factor VIII and factor IX deficiency. Cryoprecipitate provides a more concentrated source of factor VIII, von Willebrand factor, and fibrinogen, and is preferred when volume overload is a concern, particularly in cats or small dogs. The choice between FFP and cryoprecipitate depends on the suspected factor deficiency, the patient's volume status, and product availability. Factor IX is not concentrated in cryoprecipitate, so FFP or fresh whole blood is required for hemophilia B. The clinical response to transfusion is the most useful monitoring parameter. Joint bleeding should show reduced swelling and pain within 12 to 24 hours. Muscle hematomas should stabilize in size. Serial aPTT measurements can guide repeat dosing, but the correlation between aPTT correction and clinical hemostasis is imperfect. The target is to maintain factor activity above 20 to 30 percent of normal until bleeding has stopped, which typically requires repeat plasma administration every 8 to 12 hours for the first day. Current formulary and transfusion medicine references must be consulted for specific dosing and product selection guidance. ## Thrombopathia and Platelet Function Disorders ### Recognizing Primary Hemostatic Failure Platelet function disorders produce mucosal bleeding, petechiae, ecchymoses, and prolonged bleeding from small wounds. The platelet count is normal or only mildly decreased, and PT and aPTT are normal. von Willebrand disease is the most common inherited bleeding disorder in dogs, with a high prevalence in Doberman Pinschers, Scottish Terriers, and Shetland Sheepdogs. Acquired thrombopathia occurs with uremia, certain drugs, and some systemic diseases. The buccal mucosa bleeding time is the most practical point-of-care test for platelet function, but it requires a cooperative patient, a standardized incision device, and careful technique. Platelet function analyzers provide quantitative results but are not available in most emergency practices. The diagnosis of von Willebrand disease is confirmed by measuring von Willebrand factor antigen concentration, which requires submission to a reference laboratory. ### Management of Platelet Function Disorders Desmopressin acetate releases stored von Willebrand factor and factor VIII from endothelial cells and can shorten bleeding time in some dogs with mild or moderate von Willebrand disease. The response is variable and not predictable in an individual patient. For severe bleeding, cryoprecipitate or FFP provides exogenous von Willebrand factor. Platelet transfusion is not effective for von Willebrand disease because the defect is in the plasma protein, not the platelet itself. For true thrombopathia, platelet-rich plasma or fresh whole blood is the appropriate product. ## Transfusion Support in Coagulation Emergencies ### Product Selection and the Bleeding Patient The choice of blood product in a bleeding patient depends on what is deficient. Packed red blood cells restore oxygen-carrying capacity but provide negligible coagulation factors and platelets. Fresh whole blood provides red cells, labile coagulation factors, and functional platelets, and is the most complete product for a patient with combined deficiencies. Fresh frozen plasma provides stable and labile coagulation factors but no platelets or red cells. Cryoprecipitate provides factor VIII, von Willebrand factor, fibrinogen, and fibronectin in a small volume. The transfusion threshold for packed red cells in a bleeding patient is not a fixed number. The decision to transfuse red cells depends on the rate of ongoing blood loss, the patient's cardiovascular reserve, tissue oxygen delivery, and the trend in packed cell volume instead of a single measurement. A patient with acute hemorrhage and a packed cell volume of 25 percent may require transfusion while a stable patient with chronic anemia at the same value may not. The [AAHA/AAFP Fluid Therapy Guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) emphasize individualised resuscitation planning with frequent reassessment instead of formulaic triggers. ### Monitoring the Transfused Patient Every transfusion carries risk of acute hemolytic reaction, febrile non-hemolytic reaction, or transfusion-associated circulatory overload. The patient should be monitored closely during the first 30 minutes of administration, with temperature, heart rate, respiratory rate, and mucous membrane color recorded at regular intervals. Cats are at particular risk of volume overload, and slower infusion rates are required. The [RECOVER Initiative guidelines](https://recoverinitiative.org/) provide structured recommendations for recognizing and responding to adverse transfusion events, including the resuscitation of a patient who deteriorates during transfusion. Documentation should include the product type, volume, administration rate, pre-transfusion and post-transfusion vital parameters, and any adverse reactions. Serial packed cell volume and total protein measurements assess the response to red cell transfusion. Coagulation times and clinical bleeding assessment guide the response to plasma products. ## Diagnostic Algorithm for the Bleeding Patient The following table summarizes the diagnostic pathway based on initial laboratory findings. This framework assumes that point-of-care testing is available and that the clinician is working through the differential diagnosis systematically. | Initial Findings | Most Likely Diagnoses | Next Diagnostic Step | Initial Product Choice | |---|---|---|---| | Prolonged PT and aPTT, thrombocytopenia | DIC, rodenticide toxicity with concurrent blood loss | Platelet count trend, fibrinogen, D-dimer, PIVKA | FFP plus red cells as needed | | Prolonged aPTT only | Hemophilia A or B, acquired factor VIII inhibitor | Factor assays, mixing study | FFP or cryoprecipitate | | Prolonged PT only | Factor VII deficiency, early rodenticide toxicity | Repeat profile in 12 to 24 hours, PIVKA | FFP | | Normal PT and aPTT, thrombocytopenia | Primary immune-mediated thrombocytopenia, bone marrow disease | Blood smear, platelet count trend, reticulocyte count | Platelet-rich plasma or fresh whole blood if bleeding | | Normal PT and aPTT, normal platelet count, mucosal bleeding | von Willebrand disease, thrombopathia | Buccal mucosa bleeding time, vWF antigen | Cryoprecipitate or FFP | | Prolonged PT and aPTT, normal platelet count | Vitamin K-dependent factor deficiency, severe liver disease | PIVKA, bile acids, factor VII assay | FFP, vitamin K therapy | The algorithm is a guide, not a substitute for clinical judgment. A patient with severe trauma may have multiple concurrent hemostatic abnormalities, and the pattern of laboratory findings may shift over hours. Repeat testing is often more informative than a single profile. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides additional detail on interpreting coagulation test results in the context of specific diseases. ## Species and Equipment Considerations Cats present specific challenges in coagulation emergencies. Their small blood volume limits the volume of blood products that can be administered safely, and their tendency toward thromboembolic disease complicates the interpretation of coagulation profiles. Feline platelet counts are often underestimated by automated analyzers because of platelet clumping, and a blood smear review is essential before diagnosing thrombocytopenia. The normal reference intervals for coagulation times differ between dogs and cats, and laboratory-specific values should be used. Point-of-care coagulation analyzers provide rapid results but have limitations. They are less accurate at the extremes of the reference range, and results should be interpreted alongside clinical findings. A normal point-of-care profile does not exclude a mild factor deficiency or a platelet function disorder. When the clinical picture and the laboratory results conflict, the clinical picture should guide initial treatment while confirmatory testing is pending. ## Recognized Complications and Early Detection The bleeding patient deteriorates along predictable pathways. Hypovolemic shock from blood loss is the most immediate threat, but reperfusion injury, transfusion reactions, and progressive consumption of coagulation factors complicate recovery. Serial measurement of packed cell volume, total solids, lactate, and blood pressure every four to six hours identifies trends before clinical decompensation becomes obvious. A rising lactate with stable perfusion parameters suggests occult hemorrhage, particularly into the thorax, abdomen, or retroperitoneal space. Thromboembolic complications occur in patients with DIC, especially those receiving inadequate antithrombin support. Acute dyspnoea, hindlimb paresis, or unexplained hypoxemia should prompt immediate thoracic imaging and assessment of limb perfusion. The RECOVER guidelines emphasize that post-arrest patients carry particular risk of recurrent thrombosis, so any cardiac arrest in a coagulopathic patient warrants heightened surveillance for embolic events. Transfusion-associated circulatory overload and acute hemolytic reactions remain under-recognized in veterinary patients. Tachycardia that persists despite adequate volume replacement, new-onset hypertension, or respiratory effort that worsens during transfusion should halt the infusion immediately. Pre-transfusion cross-matching reduces but does not eliminate the risk of delayed hemolytic reactions. ## Common Errors and Corrective Actions Less experienced clinicians frequently misinterpret a normal platelet count as excluding primary hemostatic disease. Platelet function defects, including those induced by clopidogrel, NSAIDs, or inherited disorders such as Glanzmann thrombasthenia, produce mucosal bleeding with normal platelet numbers. Buccal mucosal bleeding time remains the practical bedside test, though it requires careful technique and a cooperative patient. A second recurring error is treating the coagulation panel instead of the patient. Prolonged PT and aPTT in a stable, non-bleeding rodenticide patient do not justify aggressive transfusion, vitamin K therapy and monitoring suffice. Conversely, a bleeding patient with near-normal clotting times may still require plasma if platelet dysfunction or hyperfibrinolysis dominates the clinical picture. Failure to recheck coagulation parameters after initiating vitamin K therapy leads to underdosing or premature discontinuation. Rodenticide toxicosis requires repeat PT assessment at 48 to 72 hours after starting therapy, then again after stopping treatment to confirm resolution. Clinicians who omit these checks risk rebound bleeding. | Observation | Likely Cause | Discriminating Check | |---|---|---| | Bleeding with normal platelet count | Platelet function defect | Buccal mucosal bleeding time, platelet function analyzer | | Prolonged PT only | Early rodenticide toxicity or vitamin K deficiency | Repeat PT in 48 hours, response to vitamin K | | Prolonged PT and aPTT with thrombocytopenia | DIC | Fibrinogen, D-dimers, blood smear for schistocytes | | Worsening dyspnoea during transfusion | Transfusion-associated circulatory overload | Respiratory rate trend, thoracic ultrasound, blood pressure | | Persistent tachycardia after volume resuscitation | Ongoing hemorrhage or transfusion reaction | Serial lactate, focused assessment with sonography for trauma, cross-match | ## Evidence Limitations and Contested Areas The veterinary literature on coagulation emergencies relies heavily on extrapolation from human medicine and small retrospective case series. Randomised controlled trials comparing transfusion strategies, antifibrinolytic use, and monitoring protocols in dogs and cats are scarce. Expert opinion diverges on several practical points. The role of recombinant activated factor VII in veterinary patients remains contested. Some specialists advocate its use in refractory hemorrhage when plasma transfusion has failed, while others cite cost, thrombotic risk, and lack of outcome data as prohibitive. Similarly, the optimal trigger for fresh frozen plasma transfusion in DIC is debated. The MSD Veterinary Manual advises that plasma transfusion should target clinical bleeding instead of laboratory values alone, but individual clinicians interpret this guidance variably. Feline coagulation testing presents particular challenges. Reference intervals differ from canine values, and sample collection artefact from difficult venepuncture is common. Point-of-care devices validated for dogs may not perform reliably in cats, and clinicians should confirm that their analyzer has feline-specific calibration before interpreting results. ## Referral, Consultation, and Reporting Immediate referral to a specialty hospital is warranted when hemorrhage continues despite appropriate initial therapy, when the patient requires mechanical ventilation, or when specialist transfusion support such as apheresis or factor concentrates is anticipated. Early telephone consultation with a criticalist or hematologist is appropriate before the patient destabilises. Laboratory involvement extends beyond routine coagulation panels. Suspected inherited factor deficiencies warrant consultation with a reference laboratory for factor-specific assays, as results guide long-term management and breeding decisions. The AVMA practice resources note that genetic testing for known mutations is available for several canine coagulopathies, and clinicians should discuss the limitations of these tests with owners. Regulatory reporting obligations vary by jurisdiction. Suspected malicious poisoning, including anticoagulant rodenticide toxicity in a non-target species, may require notification to local animal welfare authorities. The WOAH terrestrial animal health standards address reportable diseases, and while coagulopathies are not generally notifiable, clinicians should verify local requirements when a cluster of unexplained bleeding cases appears. Document all suspected toxic exposures thoroughly, including product identification when available, as this information supports both clinical management and public health surveillance. ## Frequently Asked Questions ### How Do I Prioritize Transfusion When Plasma Supply Is Limited or Cost Is Prohibitive? When plasma is scarce, first determine whether transfusion is truly necessary. A stable patient with rodenticide toxicity and no active bleeding may tolerate vitamin K therapy alone while awaiting plasma. For active bleeding, cryoprecipitate provides higher factor concentration per unit volume than fresh frozen plasma, though availability varies. If no plasma products exist, whole blood from a compatible donor supplies labile factors, albeit with lower factor density and added red cell mass. Discuss cost and prognosis openly with the owner before committing to a transfusion plan. Document the rationing decision and the clinical rationale in the medical record. Consult the [MSD Veterinary Manual](https://www.msdvetmanual.com/) for product descriptions and storage requirements. ### What Can I Do When Point-of-Care Coagulation Testing Is Unavailable? A buccal mucosal bleeding time, performed with a standard template device, offers a crude screen for primary hemostatic defects. A blood film reviewed for platelet count and morphology is mandatory. If an in-house PT/aPTT analyzer is absent, submit citrated plasma to a reference laboratory, but treat the patient while awaiting results. Clinical signs guide therapy: petechiae and mucosal bleeding suggest platelet dysfunction, while deep hematomas and body cavity bleeding suggest factor deficiency. In suspected rodenticide toxicity with consistent history and clinical signs, initiate vitamin K therapy without waiting for confirmatory testing. The [AAHA/AAFP Fluid Therapy Guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) remind us that resuscitation fluids themselves can dilute clotting factors, so use minimal crystalloid in the bleeding patient. ### How Does the Approach Differ in Cats Compared with Dogs? Cats present unique challenges. Venipuncture is more difficult, and sample volumes are smaller, so prioritize a single citrated tube for coagulation assays and a lavender-top tube for CBC. Feline platelets aggregate readily, making automated counts unreliable, a blood film estimate is often more accurate. Cats with anticoagulant rodenticide toxicity typically show pulmonary hemorrhage and dyspnoea instead of the subcutaneous bruising common in dogs. Inherited factor XII deficiency in cats prolongs aPTT without causing bleeding, so interpret prolonged aPTT cautiously in the absence of clinical hemorrhage. Transfusion reactions are more common in cats, and repeated plasma administration carries sensitization risk. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific reference intervals for coagulation parameters. ### What Records Should I Keep for a Coagulation Emergency Case? Document the presenting complaint, physical examination findings, and all laboratory results with timestamps. Record the exact product administered, including lot number, volume, and administration rate. Note the patient's response to each intervention, including serial packed cell volume and coagulation parameters. For suspected rodenticide toxicity, record the product name and concentration if known, the estimated time of exposure, and the planned duration of vitamin K therapy. Photographs of skin lesions or ecchymoses are useful for serial comparison. If the case involves a potential regulatory concern, such as a contaminated product or suspected malicious poisoning, preserve samples and follow [AVMA practice resources](https://www.avma.org/resources-tools) for reporting obligations. Clear records also support client communication and medicolegal defense. ### How Do I Explain a Coagulation Emergency to a Distressed Owner? Use plain language and concrete analogies. Explain that the blood lacks the "glue" needed to form clots, or that clotting factors are "used up" faster than the body can replace them. Describe each diagnostic step as it happens and give a realistic time frame for results. Be honest about prognosis: a rodenticide toxicity with early treatment carries a good outlook, while DIC secondary to sepsis carries a guarded one. Outline the treatment plan in stages, starting with stabilization and moving to definitive therapy. Invite questions and repeat key points. The [AVMA practice resources](https://www.avma.org/resources-tools) offer communication guidance for difficult conversations. Document the discussion, including the owner's stated understanding and consent for treatment. ### When Should I Stop Resuscitation Efforts in a Bleeding Patient? Ongoing hemorrhage despite adequate transfusion support, progressive coagulopathy, and refractory hypotension indicate a guarded to grave prognosis. Serial lactate measurements help track perfusion, a rising lactate despite resuscitation signals irreversible shock. If the patient suffers cardiac arrest during a bleeding crisis, follow the [RECOVER Initiative CPR guidelines](https://recoverinitiative.org/) for arrest management, but recognize that survival to discharge is low in this population. Discuss euthanasia candidly when the owner's financial resources are exhausted and the patient remains unstable. In cases of suspected envenomation or toxin exposure, contact a veterinary toxicology service before deciding to stop, as specific antidotes may alter the trajectory. Document the decision-making process and the owner's involvement in the final choice. ## Related Clinical & Scientific Guides * [Toxicology in Emergency Practice: Common Poisons and Diagnostic Approach](/knowledge/veterinary-medicine/emergency-critical-care/toxicology-emergency-practice-common-poisons-diagnostic-approach) * [Veterinary Cardiopulmonary Resuscitation: Post-Cardiac Arrest Care](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-cardiopulmonary-resuscitation-post-cardiac-arrest-care) * [Fluid Therapy Guidelines for Dogs and Cats: A Practical Update](/knowledge/veterinary-medicine/emergency-critical-care/fluid-therapy-guidelines-dogs-cats-practical-update) ## References and Further Reading - [COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.](https://pubmed.ncbi.nlm.nih.gov/32352535/). 2020. - [Emerging Tick-Borne Diseases.](https://pubmed.ncbi.nlm.nih.gov/31896541/). 2020. - [RECOVER Initiative Veterinary CPR Guidelines](https://recoverinitiative.org/). Veterinary Emergency and Critical Care Society. - [AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/). AAHA. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. - [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association. - [WOAH Terrestrial Animal Health Code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). WOAH. ## Related Articles - [Veterinary ICU Monitoring: Coagulation Assessment](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-icu-monitoring-coagulation-assessment) - [Veterinary ICU Monitoring: Pain Assessment and Management](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-icu-monitoring-pain-assessment-management) - [Veterinary Toxicology: Common Toxins and Emergency Management](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-toxicology-common-toxins-emergency-management) - [Electrolyte Emergencies in Dogs and Cats: Recognition and Correction](/knowledge/veterinary-medicine/emergency-critical-care/electrolyte-emergencies-dogs-cats-recognition-correction) - [Trauma Triage and Primary Survey in Small Animals](/knowledge/veterinary-medicine/emergency-critical-care/trauma-triage-primary-survey-small-animals) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.